Signal #144534 · SEC 8-K

$PYXS SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $PYXS filing catalyst

Why did $PYXS trigger an AI stock catalyst alert?

$PYXS triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.5/10). Headline: Pyxis Oncology Reports Q3 2026 Loss of $0.24/Share and Phase 1 MICVO Data. Key points: - Net loss per share narrowed to $0.24 vs. $0.35 in prior-year quarter - Micvotabart Pelidotin Phase 1 showed 36% ORR and 94% DCR in 2L+ R/M HNSCC - End-of-Phase 2 FDA feedback expected in Q1 2027, Phase 3 planned for mid-2027

How did $PYXS stock react after the SEC filing?

After the SEC 8-K for $PYXS, observed market reaction: T0 price $1.66. Past moves do not guarantee future results.

Where can I get real-time $PYXS SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $PYXS via Telegram and the VIP Web Terminal from €10/month.

$PYXS

$PYXS – Pyxis Oncology Reports Q3 2026 Loss of $0.24/Share and Phase 1 MICVO Data

Pyxis Oncology, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $PYXS

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.5 / 10)

Net loss per share narrowed to $0.24 vs. $0.35 in prior-year quarter
Micvotabart Pelidotin Phase 1 showed 36% ORR and 94% DCR in 2L+ R/M HNSCC
End-of-Phase 2 FDA feedback expected in Q1 2027, Phase 3 planned for mid-2027

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →